Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth

Core Insights - Arcutis Biotherapeutics, Inc. has promoted Mas Matsuda to executive vice president, chief legal officer, and corporate secretary, reflecting the company's commitment to strengthening its legal and compliance framework as it continues to grow and commercialize its ZORYVE portfolio [1][2] Company Overview - Arcutis is a commercial-stage biopharmaceutical company focused on innovations in immuno-dermatology, with a growing portfolio of advanced targeted topicals approved for treating major inflammatory skin diseases [5][6] - The company has achieved significant commercial growth, including six FDA approvals for its ZORYVE product line, which addresses immune-mediated skin diseases [2][3] Leadership and Strategy - Mas Matsuda has been with Arcutis since January 2022, playing a crucial role in the company's legal and compliance strategy, and has been instrumental in the development and growth of the ZORYVE franchise [2][3] - The company is entering a new phase of growth, with Matsuda's leadership expected to be critical in expanding its commercial presence and advancing its product portfolio [2][3] Product Information - ZORYVE cream and foam are indicated for the treatment of various dermatological conditions, including atopic dermatitis and plaque psoriasis, in both pediatric and adult patients [7][8] - The product line includes different formulations with specific indications for various age groups, showcasing the company's commitment to addressing diverse patient needs [7][8]